Fig. 1From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectivesEmerging therapies in EGFR ex20ins NSCLC. Conventional EGFR-TKIs have shown limited efficacy, such as erlotinib, gefitinib and afatinib. Combination therapy has become a trend in some clinical trials. Currently known and relatively mature drugs include mobocertinib, amivantamab, poziotinib and furmonertinibBack to article page